<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02239562</url>
  </required_header>
  <id_info>
    <org_study_id>20140114</org_study_id>
    <secondary_id>119219</secondary_id>
    <nct_id>NCT02239562</nct_id>
  </id_info>
  <brief_title>sPIF CLINICAL STUDY PROTOCOL FOR AUTOIMMUNE HEPATITIS</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Synthetic PreImplantation Factor (sPIF) in Autoimmune Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christopher O'Brien</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioIncept LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the safety and tolerability of synthetic
      PreImplantation Factor (sPIF) in female patients with autoimmune hepatitis. Autoimmune
      hepatitis is a disease where the patient's immune system produces an inappropriate immune
      response against their own liver. PreImplantation Factor is a substance that is secreted by
      viable fetuses during pregnancy. PIF apparently initiates both maternal tolerance preventing
      the loss/rejection of the fetus. Synthetic PIF (sPIF) successfully translates PIF endogenous
      properties to pregnant and non-pregnant immune disorders. sPIF was found to be effective in
      preclinical models of autoimmunity and transplantation (published). Specifically sPIF
      protected the liver against immune attack. In FDA mandated toxicity studies (mice, dogs),
      high-dose sPIF administration for 2 weeks followed by 2 weeks observation period demonstrated
      a high safety profile. Based on those observations the FDA has granted a Fast Track
      designation for this trial. This study will evaluate the safety, tolerability and the blood
      level of this synthetic version of this natural compound in the circulation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">April 25, 2017</completion_date>
  <primary_completion_date type="Actual">April 25, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>28 Day</time_frame>
    <description>Safety and tolerability will be evaluated by assessment of clinical laboratory tests, periodic physical examination, including vital signs measurements, and 12-lead ECG at baseline (pre-dose, Day 1) and at various time points during the treatment phases of both SAD and the MAD portions of the protocol, and by the documentation of adverse events. Concomitant medication intake will also be recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>28 Day</time_frame>
    <description>sPIF levels in the plasma will be determined at baseline, 30 (±5), 60 (±10) and 120 (±15) and 240 (±20) minutes after SQ injection using validated LC-MS/MS assay in both the SAD and MAD portions of the protocol.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory Analysis: Proof of Concept</measure>
    <time_frame>28 Day</time_frame>
    <description>Efficacy will be evaluated by change in serum alanine aminotransferase (ALT) levels from baseline to the various ascending doses</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Analysis: Pharmacodynamics</measure>
    <time_frame>28 Day</time_frame>
    <description>Serum will be collected and stored at -80±10° for possible later analysis by genomics, proteomics, peripheral blood mononuclear cell (PBMC) and cytokine analysis.</description>
  </other_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Autoimmune Hepatitis</condition>
  <arm_group>
    <arm_group_label>NORMAL Liver Function Single Ascending Dose 0.1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within each cohort (3 patients), patients with normal liver function tests will be randomized in a 2:1 ratio (active drug : placebo) to receive a single dose of sPIF or placebo as follows:
Cohort 1: Single dose 0.1 mg/kg sPIF or Placebo Day 1 given SQ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NORMAL Liver Function Single Ascending Dose 0.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within each cohort (3 patients), patients with normal liver function tests will be randomized in a 2:1 ratio (active drug : placebo) to receive a single dose of sPIF or placebo as follows:
Cohort 2: single dose 0.5 mg/kg sPIF or Placebo Day 1 given SQ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NORMAL Liver Function Single Ascending Dose 1.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within each cohort (3 patients), patients with normal liver function tests will be randomized in a 2:1 ratio (active drug : placebo) to receive a single dose of sPIF or placebo as follows:
Cohort 3: single dose 1.0 mg/kg sPIF or Placebo Day 1 given SQ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABNORMAL Liver Function Single Ascending Dose 0.1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within each cohort (3 patients), patients with abnormal liver function tests will be randomized in a 2:1 ratio (active drug : placebo) to receive a single dose of sPIF or placebo as follows:
Single dose 0.1 mg/kg sPIF or Placebo Day 1 given SQ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABNORMAL Liver Function Single Ascending Dose 0.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within each cohort (3 patients), patients with abnormal liver function tests will be randomized in a 2:1 ratio (active drug : placebo) to receive a single dose of sPIF or placebo as follows:
Single dose 0.5 mg/kg sPIF or Placebo Day 1 given SQ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABNORMAL Liver Function Single Ascending Dose 1.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within each cohort (3 patients), patients with abnormal liver function tests will be randomized in a 2:1 ratio (active drug : placebo) to receive a single dose of sPIF or placebo as follows:
Single dose 1.0 mg/kg sPIF or Placebo Day 1 given SQ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Liver Function Multiple Ascending Dose 0.1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within each cohort (3 patients), subjects with normal liver function tests will be randomized in a 2:1 ratio (active drug : placebo) to multiple doses of sPIF administered subcutaneously once a day for 5 consecutive days (Days 1 to 5):
Cohort 1: 0.1 mg/kg sPIF or Placebo Days 1-5 given SQ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Liver Function Multiple Ascending Dose 0.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within each cohort (3 patients), subjects with normal liver function tests will be randomized in a 2:1 ratio (active drug : placebo) to multiple doses of sPIF administered subcutaneously once a day for 5 consecutive days (Days 1 to 5):
Cohort 2: 0.5 mg/kg sPIF or Placebo Days 1-5 given SQ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Liver Function Multiple Ascending Dose 1.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within each cohort (3 patients), subjects with normal liver function tests will be randomized in a 2:1 ratio (active drug : placebo) to multiple doses of sPIF administered subcutaneously once a day for 5 consecutive days (Days 1 to 5):
Cohort 2: 1.0 mg/kg sPIF or Placebo Days 1-5 given SQ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abnormal Liver Function Multiple Ascending Dose 0.1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within each cohort (3 patients), subjects with abnormal liver function tests will be randomized in a 2:1 ratio (active drug : placebo) to multiple doses of sPIF administered subcutaneously once a day for 5 consecutive days (Days 1 to 5):
Cohort 1: 0.1 mg/kg sPIF or Placebo Days 1-5 given SQ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abnormal Liver Function Multiple Ascending Dose 0.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within each cohort (3 patients), subjects with abnormal liver function tests will be randomized in a 2:1 ratio (active drug : placebo) to multiple doses of sPIF administered subcutaneously once a day for 5 consecutive days (Days 1 to 5):
Cohort 1: 0.5 mg/kg sPIF or Placebo Days 1-5 given SQ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abnormal Liver Function Multiple Ascending Dose 1.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within each cohort (3 patients), subjects with abnormal liver function tests will be randomized in a 2:1 ratio (active drug : placebo) to multiple doses of sPIF administered subcutaneously once a day for 5 consecutive days (Days 1 to 5):
Cohort 1: 1.0 mg/kg sPIF or Placebo Days 1-5 given SQ</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sPIF</intervention_name>
    <arm_group_label>NORMAL Liver Function Single Ascending Dose 0.1</arm_group_label>
    <arm_group_label>NORMAL Liver Function Single Ascending Dose 0.5</arm_group_label>
    <arm_group_label>NORMAL Liver Function Single Ascending Dose 1.0</arm_group_label>
    <arm_group_label>ABNORMAL Liver Function Single Ascending Dose 0.1</arm_group_label>
    <arm_group_label>ABNORMAL Liver Function Single Ascending Dose 0.5</arm_group_label>
    <arm_group_label>ABNORMAL Liver Function Single Ascending Dose 1.0</arm_group_label>
    <arm_group_label>Normal Liver Function Multiple Ascending Dose 0.1</arm_group_label>
    <arm_group_label>Normal Liver Function Multiple Ascending Dose 0.5</arm_group_label>
    <arm_group_label>Normal Liver Function Multiple Ascending Dose 1.0</arm_group_label>
    <arm_group_label>Abnormal Liver Function Multiple Ascending Dose 0.1</arm_group_label>
    <arm_group_label>Abnormal Liver Function Multiple Ascending Dose 0.5</arm_group_label>
    <arm_group_label>Abnormal Liver Function Multiple Ascending Dose 1.0</arm_group_label>
    <other_name>synthetic PreImplantation Factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>NORMAL Liver Function Single Ascending Dose 0.1</arm_group_label>
    <arm_group_label>NORMAL Liver Function Single Ascending Dose 0.5</arm_group_label>
    <arm_group_label>NORMAL Liver Function Single Ascending Dose 1.0</arm_group_label>
    <arm_group_label>ABNORMAL Liver Function Single Ascending Dose 0.1</arm_group_label>
    <arm_group_label>ABNORMAL Liver Function Single Ascending Dose 0.5</arm_group_label>
    <arm_group_label>ABNORMAL Liver Function Single Ascending Dose 1.0</arm_group_label>
    <arm_group_label>Normal Liver Function Multiple Ascending Dose 0.1</arm_group_label>
    <arm_group_label>Normal Liver Function Multiple Ascending Dose 0.5</arm_group_label>
    <arm_group_label>Normal Liver Function Multiple Ascending Dose 1.0</arm_group_label>
    <arm_group_label>Abnormal Liver Function Multiple Ascending Dose 0.1</arm_group_label>
    <arm_group_label>Abnormal Liver Function Multiple Ascending Dose 0.5</arm_group_label>
    <arm_group_label>Abnormal Liver Function Multiple Ascending Dose 1.0</arm_group_label>
    <other_name>Ringer's lactate to mimic sPIF solution for injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, aged from 18 to 70 years old, of non-child bearing potential (to avoid the
             possibility if antibodies are formed to sPIF this could put the patient at risk for
             future fertility)

          -  Females must be either

               -  Postmenopausal for greater than two years,

               -  Postmenopausal for less than two years with an FSH level greater &gt; 40mIU/mL

               -  Or documented as surgically sterile (bilateral tubal ligation, bilateral
                  oophorectomy or post-hysterectomy) at least three months prior to the screening
                  evaluation

          -  Autoimmune hepatitis as documented by a:

               -  Pretreatment score ≥15

               -  Or a post-treatment score of ≥17 on the International Criteria for the Diagnosis
                  of Autoimmune Hepatitis (Appendix 2)

          -  Treatment with prednisone and/or other oral, immunosuppressive drug(s) must have been
             stabilized for at least 6 weeks prior to screening for this study.

          -  Stable ALT levels with a fixed dose of their immunosuppressant medications

          -  Subjects do not have to have had a documented relapse after completion of an initial
             course of therapy

          -  Permitted concomitant immunosuppressant medications will include

               -  Azathioprine dose equal to/or less 100 mg per day,

               -  Budesonide dose equal to/or less 9 mg per day,

               -  Mycophenolate mofetil equal to/or less 3000 mg per day,

               -  Prednisone equal to/or less than 10 mg per day

               -  Ursodeoxycholic acid equal to/or less than 1000 mg per day

          -  In the judgment of the Investigator, be in reasonable general health, based on review
             of the results of a screening evaluation (to include physical examination, measurement
             of vital signs, 12-lead ECG trace and the collection of blood and urine for routine
             clinical laboratory testing), performed no more than 30 days prior to Day 1 of study.

          -  Patients must agree to abstain from alcohol use during their participation in the
             study protocol.

          -  Alanine aminotransferase (ALT) levels of no more than five times the upper limit of
             normal (reference) range (ULN) at the screening evaluation.

          -  Normal renal function as determined by a serum creatinine

          -  A female of childbearing potential who is documented as either surgically sterile
             (bilateral tubal ligation, bilateral oophorectomy or post-hysterectomy at least 3
             months prior to the screening evaluation) or post-menopausal for ≥ 2 years.

        Exclusion Criteria:

          -  Any other forms of chronic liver disease.

          -  Decompensated liver disease defined on the basis of any one of the following
             laboratory parameters at the screening evaluation: total bilirubin &gt; 1.5 × ULN,
             prothrombin time &gt; 1.2 × ULN, platelets ≤ 100,000/mm3, or albumin &lt; 3 g/dL OR current
             or prior history of clinical hepatic decompensation (e.g., ascites, jaundice,
             encephalopathy or variceal hemorrhage).

          -  Hemoglobin &lt; 11 g/dL at the screening evaluation.

          -  Serological evidence of infection with HIV upon review of the medical record.

          -  Evidence of hepatocellular carcinoma (i.e., screening α-fetoprotein &gt; 50 ng/mL or
             other standard of care measure).

          -  Subjects with, or a history of clinically significant oncologic, pulmonary, hepatic,
             gastrointestinal, renal, other cardiovascular, hematologic, metabolic, endocrine,
             neurologic, immunologic or hematologic illness or any other major medical disorder
             that, in the judgment of the Investigator, would interfere with subject treatment,
             assessment or compliance with the protocol or should otherwise preclude their
             participation in this trial.

          -  Have received therapy with potentially hepatotoxic drugs within 3 months (90 days)
             prior to Day 1 or are expected to receive such therapy during the study.

          -  Patient who are expected to receive a change in their immunosuppressant therapies
             during the protocol.

          -  Patients who may receive chemotherapeutic agents (e.g., corticosteroids,
             immunoglobulins and other immune- or cytokine-based therapies) during the study for
             any other medical condition.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher B. O'Brien, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Liver Diseases; University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chief Scientist, BIOINCEPT, LLC / Chairman, (SEIP) / Director, Ob&amp;Gyn CAMcare Health Center</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08003-3157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2014</study_first_submitted>
  <study_first_submitted_qc>September 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2014</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Christopher O'Brien</investigator_full_name>
    <investigator_title>Professor of Clinical Medicine</investigator_title>
  </responsible_party>
  <keyword>sPIF</keyword>
  <keyword>synthetic PreImplantation Factor</keyword>
  <keyword>Autoimmune</keyword>
  <keyword>Liver</keyword>
  <keyword>Hepatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Autoimmune</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>January 16, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

